As an increase in the PDHC activity by a PDK4 inhibitor promotes glucose oxidation and lowers the blood glucose concentration, small molecule inhibitors for PDKs are promising therapeutic agents for patients with metabolic diseases. This evidence concerns the gene PDK4 and metabolic disease.